Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. [electronic resource]
Producer: 20120823Description: 2056-65 p. digitalISSN:- 1557-3265
- Adenocarcinoma, Follicular -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Benzimidazoles -- adverse effects
- Carcinoma
- Carcinoma, Papillary
- Diarrhea -- chemically induced
- Exanthema -- chemically induced
- Fatigue -- chemically induced
- Female
- Genotype
- Humans
- Iodine Radioisotopes -- therapeutic use
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Mutation
- Pharmacogenetics
- Proto-Oncogene Proteins B-raf -- genetics
- Thyroid Cancer, Papillary
- Thyroid Neoplasms -- drug therapy
- Treatment Outcome
- ras Proteins -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.